Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ChAdOx1 MERS vaccine - Barinthus Biotherapeutics

Next Previous
Drug Profile

ChAdOx1 MERS vaccine - Barinthus Biotherapeutics

Alternative Names: ChAdOx1 MERS vaccine; MERS vaccine - Barinthus Biotherapeutics; MERS-CoV vaccine – Barinthus Biotherapeutics; VTP-500

Latest Information Update: 13 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Korea Investment Partners; Vaccitech
  • Developer Barinthus Biotherapeutics; University of Oxford
  • Class COVID-19 vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Middle East respiratory syndrome coronavirus

Most Recent Events

  • 13 May 2026 ChAdOx1 MERS vaccine is available for licensing as of 31 Jan 2025. https://www.sec.gov/ix?doc=/Archives/edgar/data/1828185/000182818526000012/brns-20251231.htm
  • 28 Oct 2025 No recent reports of development identified for phase-I development in Middle-East-respiratory-syndrome-coronavirus(Prevention) in United Kingdom (IM)
  • 11 Apr 2025 Adverse events and immunogenicity data from phase I trial in Middle East respiratory syndrome coronavirus presented at the 35th Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top